Get started
Author

Muriel Habibian

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
2013 · Gwenaelle Gravis, Karim Fizazi, et al. · The Lancet Oncology · 745
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
2015 · Gwenaelle Gravis, Jean-Marie Boher, et al. · European Urology · 459
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
2016 · Christian Carrie, Ali Hasbini, et al. · The Lancet Oncology · 365
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
2018 · Gwenaelle Gravis, Jean-Marie Boher, et al. · European Urology · 253
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
2015 · Karim Fizazi, Laura Faivre, et al. · The Lancet Oncology · 239
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial
2014 · Karim Fizazi, Lance Pagliaro, et al. · The Lancet Oncology · 207
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model
2014 · Gwenaelle Gravis, Jean-Marie Boher, et al. · European Urology · 127
Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)
2014 · Gwenaelle Gravis, Patricia Marino, et al. · European Journal of Cancer · 69
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial
2017 · Pernelle Lavaud, Gwenaëlle Gravis, et al. · European Urology · 63
Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU)
2015 · Paul Sargos, Stéphane Guerif, et al. · Cancer Treatment Reviews · 47
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.
2015 · Gwenaelle Gravis, Jean-Marie Boher, et al. · Journal of Clinical Oncology · 39
Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
2011 · B. M. Dubray, V. Beckendorf, et al. · Journal of Clinical Oncology · 36
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial
2015 · Pierre Blanchard, Laura Faivre, et al. · International Journal of Radiation Oncology*Biology*Physics · 34
Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
2016 · Bernard M. Dubray, Julia Salleron, et al. · Journal of Clinical Oncology · 31
A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.
2013 · Karim Fizazi, Lance C. Pagliaro, et al. · Journal of Clinical Oncology · 31
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases
2017 · Y. Loriot, L. Pagliaro, et al. · European Journal of Cancer · 23
Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer
2018 · Claudia S.E.W. Schuurhuizen, Patricia Marino, et al. · Journal of the National Comprehensive Cancer Network · 22
PDF
Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT).
2016 · Karim Fizazi, Aude Flechon, et al. · Journal of Clinical Oncology · 17
Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—NCT00423475.
2015 · Christian Carrie, Ali Hasbini, et al. · Journal of Clinical Oncology · 14
A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.
2013 · Karim Fizazi, Lance C. Pagliaro, et al. · Journal of Clinical Oncology · 14
Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.
2017 · Bernard J. Escudier, Sylvie Chabaud, et al. · Journal of Clinical Oncology · 12
Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.
2014 · Karim Fizazi, Agnes Laplanche, et al. · Journal of Clinical Oncology · 12
Rôle de la radiothérapie ablative des métastases chez les patients atteints de cancer de la prostate oligométastatique hormonosensible : un essai du Groupe d’étude des tumeurs urogénitales et de l’Association française d’urologie
2017 · P. Blanchard, S. Foulon, et al. · Cancer/Radiothérapie · 9
Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial
2017 · P. Marino, P. Sfumato, et al. · European Journal of Cancer · 9
The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
2017 · Stephane Gilles Guerif, Igor Latorzeff, et al. · Journal of Clinical Oncology · 9
Works count: 56
Citation count: 2,984
H-index: 17
I10-index: 22
Year
Topic
Type